1st Quarter - Amendment

SHIRE PHARMACEUTICALS LLC for SHIRE PHARMACEUTICALS LLC

Firm
Client
Income
—
Expenses
$110,000
Expense method
A: Lobbying Disclosure Act definitions

Versions of this report

Every filing the register holds for this firm, client and period, oldest first. The most recent one is the version LegiList counts.

Filing Filed Amount Counted
1st Quarter - Report Apr 20, 2012 $100,000 Replaced
1st Quarter - Amendment (this page) Jul 20, 2012 $110,000 Yes

What was lobbied

One issue area, each in the filer's own words, with who lobbied on it and where.

Pharmacy PHA

Issues relating to R&D funding for rare disease products, biosimilars and other products; drug shortages; Prescription Drug User Fee Act (PDUFA) reauthorization; exclusivity periods; orphan drugs; fast track and accelerated approvals; health care reform implementation; drug innovation and patient access H.R. 2245, Preserving Access to Life Saving Medications Act; H.R. 3839, Drug Shortage Prevention Act of 2012; H.R. 3737, Unlocking Lifesaving Treatments for Rare-Diseases Act (ULTRA); H.R. 4132, Faster Access to Specialized Treatments (FAST) Act; S. 296, Preserving Access to Life Saving Medications Act; S. 606, Creating Hope Act; S. 2113, Transforming the Regulatory Environment to Accelerate Access to Treatment (TREAT) Act

LobbyistCovered position, as disclosed
EDWARD BUCKLEY —

Contacted: SENATE; Food & Drug Administration (FDA); HOUSE OF REPRESENTATIVES

Bills named: H.R. 3737 (112th), H.R. 4132 (112th), S. 606 (112th), H.R. 2245 (112th), S. 2113 (112th), H.R. 3839 (112th), S. 296 (112th)

Support LegiList

This page is free, carries no paywall, and is built and maintained by one person. If the record here is useful to you, a few dollars keeps it going.

Processed by Stripe in a separate window. LegiList never sees card details. Other amounts

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.